MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein.
about
High throughput RNAi assay optimization using adherent cell cytometryTwo myristoylated alanine-rich C-kinase substrate (MARCKS) paralogs are required for normal development in zebrafish.Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interferenceCurrent siRNA targets in the prevention and treatment of intimal hyperplasia.Fibroblast Migration Is Regulated by Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Protein.MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.The effects of transfection reagent polyethyleneimine (PEI) and non-targeting control siRNAs on global gene expression in human aortic smooth muscle cells.Angiotensin-II and MARCKS: a hydrogen peroxide- and RAC1-dependent signaling pathway in vascular endothelium.MARCKS protein mediates hydrogen peroxide regulation of endothelial permeability.Myristoylated Alanine-Rich Protein Kinase Substrate (MARCKS) Regulates Small GTPase Rac1 and Cdc42 Activity and Is a Critical Mediator of Vascular Smooth Muscle Cell Migration in Intimal Hyperplasia Formation.Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts.MARCKS is involved in methylmercury-induced decrease in cell viability and nitric oxide production in EA.hy926 cells6q21-22 deletion syndrome with interrupted aortic arch.Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.Endothelial cells are susceptible to rapid siRNA transfection and gene silencing ex vivo.RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.The MARCKS protein amount is differently regulated by calpain during toxic effects of methylmercury between SH-SY5Y and EA.hy926 cells.
P2860
Q33881581-0CABCBA8-55FA-44AB-9D39-45B7250BF69CQ33918406-1FF74231-A6D3-4B82-BF4A-2349F88E6C85Q34355725-B0413F4C-FC90-476E-9029-B7E11B374B35Q34691876-EFFEC77E-5DCB-487E-A3A5-552F53874CE9Q34805664-08D301EF-0BC7-4061-8854-3A92E85043E7Q35830288-8CBE96FE-369C-4A6D-917F-B697499BCF1BQ35884530-10DB1FF2-3AB7-46FD-B2A4-DB6271B16247Q36217398-760E7613-0953-4C65-8F51-E9C786E73990Q36236148-29D7B1A8-F18C-4C78-9F12-491C6C01EAECQ36835981-BE2B614D-724E-4C6D-A77B-1F7DA1F862D5Q37593277-11C7E91B-8D69-468F-B3E1-8FE923D267FDQ38734458-6E166B25-644D-43B2-89F3-2BC645B73ABDQ38894226-94B975C9-1DCB-4263-B239-520CBCFAC085Q39348963-3B62934A-72E5-4E40-9D08-B2D5E4E38172Q41357917-8038FBE1-87BF-47FF-957F-F207D2FAA4E0Q42048496-0D4A20F1-5DEE-4BD6-A7DC-2102B95AD96EQ47147564-FA6EB61A-A284-4402-851B-2BAC554552FD
P2860
MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@en
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@nl
type
label
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@en
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@nl
prefLabel
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@en
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@nl
P2093
P2860
P356
P1433
P1476
MARCKS silencing differentiall ...... hyperplasia in saphenous vein.
@en
P2093
Christiane Ferran
Frank W LoGerfo
Gautam V Shrikhande
Junaid Y Malek
Leena Pradhan
Michelle C Martin
Nicholas D Andersen
Thomas S Monahan
P2860
P304
P356
10.1096/FJ.08-114173
P407
P577
2008-10-21T00:00:00Z